跳至主要内容
临床试验/EUCTR2018-000142-18-FI
EUCTR2018-000142-18-FI进行中(未招募)1 期

Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care

Turku University Hospital0 个研究点目标入组 20 人开始时间: 2018年5月8日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Diagnosed ALS
  • 2.Age = 18 years
  • 3.Written informed consent from the patient or adjacent
  • 4.Finnish spoken as mother language
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Previous history of intolerance to the study drug or related compounds and additives.
  • 2.Significant cognitive dysfunction or lack of ability to communicate
  • 3.Psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.

研究者

相似试验

Feasibility and effects of subcutaneously given... | 临床试验